13 results on '"Bhatraju, Elenore"'
Search Results
2. Substance Use and Mental Health Comorbidities and Receipt of Specialty Care Among Patients Enrolled in a Low-Barrier HIV Clinic.
- Author
-
Altwies, Eden E., Zinsli, Kaitlin A., Chwastiak, Lydia, Tsui, Judith I., Bhatraju, Elenore P., Ramchandani, Meena S., Golden, Matthew R., and Dombrowski, Julia C.
- Subjects
SUBSTANCE abuse ,ACADEMIC medical centers ,RESEARCH methodology ,MENTAL health ,RETROSPECTIVE studies ,HOUSING stability ,RESEARCH funding ,MENTAL depression ,PATIENT care ,DEMOGRAPHIC characteristics ,COMORBIDITY ,HIV ,MENTAL illness - Abstract
Low-barrier care is one model of a differentiated service delivery approach for people with HIV (PWH) who are not engaged in conventionally-organized HIV care. Although psychiatric and substance use disorders are common among patients in low-barrier clinics, approaches to behavioral health service delivery within this context have not been well-described. We conducted a descriptive analysis using retrospective review of medical records to evaluate substance use and psychiatric comorbidities and receipt of behavioral health services among patients in the Max Clinic in Seattle, Washington. Among 227 patients enrolled from 2015 to mid-2020, most had a history of hazardous substance use (85%), a psychiatric diagnosis (69%) or unstable housing (69%) documented in the medical record. Less than half of patients referred for depression treatment (33%) or for opioid use disorder treatment (40%) completed even one specialty care visit. More effective approaches are needed to engage patients in behavioral health services within the context of low-barrier HIV care. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Critical care for patients with substance use disorders.
- Author
-
Steel, Tessa L., Bhatraju, Elenore P., and Hills-Dunlap, Kelsey
- Published
- 2023
- Full Text
- View/download PDF
4. Post-traumatic stress disorder and risky opioid use among persons living with HIV and chronic pain.
- Author
-
Bhatraju, Elenore, Liebschutz, Jane M., Lodi, Sara, Forman, Leah S., Lira, Marlene C., Kim, Theresa W., Colasanti, Jonathan, del Rio, Carlos, Samet, Jeffrey H., and Tsui, Judith I.
- Subjects
HIV infections ,CHRONIC pain ,STATISTICS ,SUBSTANCE abuse ,SCIENTIFIC observation ,CONFIDENCE intervals ,MULTIVARIATE analysis ,MULTIPLE regression analysis ,POST-traumatic stress disorder ,BENZODIAZEPINES ,MORPHINE ,ALCOHOL drinking ,DESCRIPTIVE statistics ,RESEARCH funding ,OPIOID analgesics ,DATA analysis ,DATA analysis software ,PSYCHOLOGY of HIV-positive persons ,TRANQUILIZING drugs - Abstract
Persons with HIV (PWH) experience chronic pain and Post-Traumatic Stress Disorder (PTSD) at higher rates than the general population, and more often receive opioid medications to treat chronic pain. A known association exists between PTSD and substance use disorders, but less is known about the relationship between PTSD and risky opioid use among PWH taking prescribed opioid medications. In this observational study of PWH on long-term opioid medications for pain we examined associations between PTSD symptom severity based on the Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5, response range 0-80) and the following outcomes: 1) risk for opioid misuse (COMM score ≥13); 2) risky alcohol use (AUDIT score ≥8); 3) concurrent benzodiazepine prescription; and 4) morphine equivalent dose. Among 166 patients, 38 (23%) had a PCL-5 score over 38, indicating high PTSD symptom burden. Higher PCL-5 score (per 10 point difference) was associated with increased odds of opioid misuse (aOR 1.55; 95%CI: 1.31-1.83) and risky drinking (aOR: 1.28;1.07-1.52). No significant association was observed between PCL-5 score and benzodiazepine prescriptions or morphine equivalent dose. These findings suggest that when addressing alcohol and opioid use in PWH on long term opioid therapy, attention to PTSD symptoms is especially important given the higher risk for risky alcohol and opioid use among patients with this common comorbid condition. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder.
- Author
-
Bhatraju, Elenore P., Radick, Andrea C., Leroux, Brian G., Kim, Theresa W., Samet, Jeffrey H., and Tsui, Judith I.
- Subjects
OPIOID abuse ,BUPRENORPHINE ,OPIOIDS ,RANDOMIZED controlled trials ,LOG-linear models - Abstract
Background: Buprenorphine is a partial mu opioid agonist medication that has been shown to decrease non-prescribed opioid use, cravings, and opioid related morbidity and mortality. There is an assumption that full adherence is needed to achieve ideal treatment outcomes, and that non-adherence is associated with ongoing opioid use. However, literature documenting the strength of that assertion is lacking. Objectives: Evaluate the association between daily buprenorphine adherence and illicit opioid use. Methods: Secondary analysis of a 12-week randomized controlled trial of adults with opioid use disorder who recently initiated buprenorphine. Weekly study visits included self-report of daily buprenorphine adherence over the past 7 days (Timeline Follow Back method) and urine drug tests (UDT). A log-linear regression model accounting for clustering by participant was used to assess the association between buprenorphine adherence and illicit opioid use. Buprenorphine adherence was measured as a continuous variable (0–7 days). Results: Among 78 participants (56 men, 20 women, 2 nonbinary) with 737 visits, full 7-day adherence was reported at 70% of visits. The predominant form of non-adherence was missed doses (92% of cases). Each additional day of adherence was associated with an 8% higher rate of negative UDT for illicit opioids (RR = 1.08; 95% CI:1.03–1.13, p =.0002). Conclusion: In this sample of participants starting buprenorphine, missed doses were not uncommon. Fewer missed days was significantly associated with a lower risk of illicit opioid use. These findings suggest that efforts to minimize the number of missed days of buprenorphine are beneficial for treatment outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. "Sign Me Up": a qualitative study of video observed therapy (VOT) for patients receiving expedited methadone take-homes during the COVID-19 pandemic.
- Author
-
Darnton, James B., Bhatraju, Elenore P., Beima-Sofie, Kristin, Michaels, Alyssa, Hallgren, Kevin A., Soth, Sean, Grekin, Paul, Woolworth, Steve, and Tsui, Judith I.
- Subjects
COVID-19 pandemic ,METHADONE hydrochloride ,TREATMENT programs ,HEALTH services accessibility ,PATIENT safety - Abstract
Background: Federal and state regulations require frequent direct observation of methadone ingestion at an Opioid Treatment Program (OTP)—a requirement that creates barriers to patient access. Video observed therapy (VOT) may help to address public health and safety concerns of providing take-home medications while simultaneously reducing barriers to treatment access and long-term retention. Evaluating user experiences with VOT is important for understanding the acceptability of this strategy. Methods: We conducted a qualitative evaluation of a clinical pilot program of VOT via smartphone that was rapidly implemented between April and August 2020 during the COVID-19 pandemic within three opioid treatment programs. In the program, selected patients submitted video recordings of themselves ingesting methadone take-home doses, which were asynchronously reviewed by their counselor. We recruited participating patients and counselors for semi-structured, individual interviews to explore their VOT experiences after program completion. Interviews were audio recorded and transcribed. Transcripts were analyzed using thematic analysis to identify key factors influencing acceptability and the effect of VOT on the treatment experience. Results: We interviewed 12 of the 60 patients who participated in the clinical pilot and 3 of the 5 counselors. Overall, patients were enthusiastic about VOT, noting multiple benefits over traditional treatment experiences, including avoiding frequent travel to the clinic. Some noted how this allowed them to better meet recovery goals by avoiding a potentially triggering environment. Most appreciated having increased time to devote to other life priorities, including maintaining consistent employment. Participants described how VOT increased their autonomy, allowed them to keep treatment private, and normalized treatment to align with other medications that do not require in-person dosing. Participants did not describe major usability issues or privacy concerns with submitting videos. Some participants reported feeling disconnected from counselors while others felt more connected. Counselors felt some discomfort in their new role confirming medication ingestion but saw VOT as a useful tool for select patients. Conclusions: VOT may be an acceptable tool to achieve equipoise between lowering barriers to treatment with methadone and protecting the health and safety of patients and their communities. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
- Author
-
Barry, Michael P., Austin, Elizabeth J., Bhatraju, Elenore P., Glick, Sara N., Stekler, Joanne D., Tung, Elyse L., Hansen, Ryan N., Williams, Emily C., Gojic, Alexander J., Pickering, Eleanor I., and Tsui, Judith I.
- Subjects
PRE-exposure prophylaxis ,HEPATITIS C ,HEALTH attitudes ,DRUG abuse ,HIV - Abstract
Background: The incidence of HIV among persons who inject drugs (PWID) in the USA has been increasing since 2014, signaling the need to identify effective ways to engage PWID in HIV prevention services, namely pre-exposure prophylaxis (PrEP). Yet, the uptake of PrEP in this population is minimal compared to other populations at risk of HIV acquisition. In this work, we sought to explore knowledge, attitudes, and perspectives of PrEP acceptability among PWID. Methods: In the context of a pilot study to explore the acceptability of pharmacy-based hepatitis C virus (HCV) treatment, we conducted semi-structured interviews (n = 24) and focus groups (n = 4, 16 participants) with people who were living with HCV and reported active injection drug use (≤ 90 days since last use). Participants were asked open-ended questions about their familiarity with and motivation to use PrEP. As part of a sub-analysis focused on PrEP, qualitative data were analyzed using a Rapid Assessment Process, where three coders used structured templates to summarize qualitative data and iteratively reviewed coded templates to identify themes. Participants also completed short quantitative questionnaires regarding drug use history and attitudes toward health concerns. Results: Forty-seven percent of participants expressed having little or no concern regarding HIV acquisition. Targeted analyses focused on HIV prevention identified three themes, which help characterize behavioral determinants of nonadoption. First, knowledge of PrEP was limited among PWID and influenced by infrequent open community discussions around HIV risk. Second, PWID perceived sexual behaviors—but not injection drug use—as a motivator for HIV risk prevention. Finally, PWID identified many individual and environmental barriers that hinder PrEP uptake. Conclusion: Among PWID, PrEP is rarely discussed and concerns about the feasibility of using daily PrEP are common. Taken with the prevalent perception that drug use is not a high risk for HIV acquisition, our findings point to opportunities for public health work to target PrEP education to PWID and to leverage other successful interventions for PWID as an opportunity to provide PrEP to this vulnerable population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
- Author
-
Bhatraju, Elenore P., Klein, Jared W., Hall, Allana N., Chen, David R., Iles-Shih, Matthew, Tsui, Judith I., and Merrill, Joseph O.
- Published
- 2022
- Full Text
- View/download PDF
9. Mortality in an Opioid Treatment Program.
- Author
-
Bhatraju, Elenore P., Fuller, Caitlin, Grekin, Paul, Rockman, Shay, and Peavy, K. Michelle
- Subjects
TREATMENT programs ,DRUG toxicity ,SELF-poisoning ,POISONING ,ELECTRONIC health records ,OPIOIDS ,OPIOID abuse - Abstract
This retrospective study examined mortality in an Opioid Treatment Program (OTP) with policies designed to admit and retain patients with as few barriers as possible. Methadone provided in the context of an OTP is known to decrease mortality and morbidity. Historically, patients have been discharged or turned away because of continued substance use. We examined patient deaths over three years in an OTP serving approximately 2400 patients daily. Demographics and causes of death were gathered from electronic health records and medical examiner reports. Pairwise comparisons were used to compare drug poisoning versus non-drug poisoning deaths. There were 155 deaths during the study period. The average age was 54, and half of the participants had positive results on their most recent drug screen. Forty one (26%) died from "drug poisoning." Drug poisoning deaths were more common among patients who: 1) had recent positive drug test results; 2) had documented alprazolam use; 3) were younger; 4) had shorter treatment durations; 5) were female. The majority of deaths were among long-term patients over 50 and were not caused by drug poisoning. These results support keeping patients in treatment despite ongoing drug use, and linking them to appropriate primary care. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Evaluation of Bundled Interventions for Patients With Opioid Use Disorder Experiencing Homelessness Receiving Extended Antibiotics for Severe Infection.
- Author
-
Beieler, Alison M, Klein, Jared W, Bhatraju, Elenore, Iles-Shih, Matthew, Enzian, Leslie, and Dhanireddy, Shireesha
- Subjects
OPIOID abuse ,HOMELESSNESS ,ANTIBIOTICS ,COMMUNICABLE diseases ,ODDS ratio - Abstract
Hospitalizations for serious infections in patients with opioid use disorder (OUD) experiencing homelessness are common. Patients receiving 4 interventions (infectious disease consultation, addiction consultation, case management, and medications for OUD [MOUD]) had higher odds of clinical cure (unadjusted odds ratio [OR], 3.15; P = .03; adjusted OR, 3.03; P = .049) and successful retention in addiction care at 30 days (unadjusted OR, 5.46; P = .01; adjusted OR, 6.36; P = .003). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Identification and Management of Opioid Use Disorder in Primary Care: an Update.
- Author
-
Donroe, Joseph H., Bhatraju, Elenore P., Tsui, Judith I., and Edelman, E. Jennifer
- Abstract
Purpose Of Review: The rising prevalence of opioid use disorder (OUD) and related complications in North America coupled with limited numbers of specialists in addiction medicine has led to large gaps in treatment. Primary care providers (PCPs) are ideally suited to diagnose and care for people with OUD and are increasingly being called upon to improve access to care. This review will highlight the recent literature pertaining to the care of patients with OUD by PCPs.Recent Findings: The prevalence of patients with OUD in primary care practice is increasing, and models of office-based opioid treatment (OBOT) are evolving to meet local needs of both ambulatory practices and patients. OBOT has been shown to increase access to care and demonstrates comparable outcomes when compared to more specialty-driven care. OBOT is an effective means of increasing access to care for patients with OUD. The ideal structure of OBOT depends on local factors. Future research must explore ways to increase the identification and diagnosis of patients with OUD, improve treatment retention rates, reduce stigma, and promote interdisciplinary approaches to care. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
- Author
-
Bhatraju, Elenore Patterson, Grossman, Ellie, Tofighi, Babak, McNeely, Jennifer, DiRocco, Danae, Flannery, Mara, Garment, Ann, Goldfeld, Keith, Gourevitch, Marc N., and Lee, Joshua D.
- Subjects
BUPRENORPHINE ,DRUG abuse treatment ,OPIOID abuse ,TREATMENT of drug addiction ,HEALTH outcome assessment ,PRIMARY care ,PUBLIC sector - Abstract
Background: Buprenorphine maintenance for opioid dependence remains of limited availability among underserved populations, despite increases in US opioid misuse and overdose deaths. Low threshold primary care treatment models including the use of unobserved, "home," buprenorphine induction may simplify initiation of care and improve access. Unobserved induction and long-term treatment outcomes have not been reported recently among large, naturalistic cohorts treated in low threshold safety net primary care settings. Methods: This prospective clinical registry cohort design estimated rates of induction-related adverse events, treatment retention, and urine opioid results for opioid dependent adults offered buprenorphine maintenance in a New York City public hospital primary care office-based practice from 2006 to 2013. This clinic relied on typical ambulatory care individual provider-patient visits, prescribed unobserved induction exclusively, saw patients no more than weekly, and did not require additional psychosocial treatment. Unobserved induction consisted of an in-person screening and diagnostic visit followed by a 1-week buprenorphine written prescription, with pamphlet, and telephone support. Primary outcomes analyzed were rates of induction-related adverse events (AE), week 1 drop-out, and long-term treatment retention. Factors associated with treatment retention were examined using a Cox proportional hazard model among inductions and all patients. Secondary outcomes included overall clinic retention, buprenorphine dosages, and urine sample results. Results: Of the 485 total patients in our registry, 306 were inducted, and 179 were transfers already on buprenorphine. Post-induction (n = 306), week 1 drop-out was 17%. Rates of any induction-related AE were 12%; serious adverse events, 0%; precipitated withdrawal, 3%; prolonged withdrawal, 4%. Treatment retention was a median 38 weeks (range 0-320) for inductions, compared to 110 (0-354) weeks for transfers and 57 for the entire clinic population. Older age, later years of first clinic visit (vs. 2006-2007), and baseline heroin abstinence were associated with increased treatment retention overall. Conclusions: Unobserved "home" buprenorphine induction in a public sector primary care setting appeared a feasible and safe clinical practice. Post-induction treatment retention of a median 38 weeks was in line with previous naturalistic studies of real-world office-based opioid treatment. Low threshold treatment protocols, as compared to national guidelines, may compliment recently increased prescriber patient limits and expand access to buprenorphine among public sector opioid use disorder patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Revising residents' addiction experience: a 1-week intensive course.
- Author
-
Bhatraju, Elenore Patterson, Chang, Andrew, Taff, Jessica, and Hanley, Kathleen
- Subjects
SUBSTANCE-induced disorders ,CURRICULUM planning ,PRIMARY care ,INTERNS (Medicine) ,EXPERIENTIAL learning ,PROFESSIONAL education ,CURRICULUM ,INTERNSHIP programs ,PRIMARY health care ,SUBSTANCE abuse - Abstract
The article provides information on a medical school course designed for primary care internal medicine interns to better prepare them to address substance use (SU) disorders. It details the learner-centered, experiential education model used to address the SU disorder knowledge gap.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.